Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

The Case For Expanding Access To Highly Active Antiretroviral Therapy To Curb The Growth Of The HIV Epidemic

J. Montaner, R. Hogg, E. Wood, T. Kerr, P. Harrigan
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
examine here the potential role of HAART in HIV prevention and the resulting eff ect this would have on the cost-eff ectiveness of the treatment. We also discuss a theoretical HAART-driven strategy to control the continued expansion of the HIV/AIDS pandemic.
This paper references
10.1001/JAMA.284.24.3123
Association of initial CD4 cell count and viral load with response to highly active antiretroviral therapy.
R. Chaisson (2000)
10.1016/S1473-3099(05)70162-6
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.
E. Wood (2005)
10.1016/S0140-6736(07)61025-3
HIV treatment, injection drug use, and illicit drug policies
E. Wood (2007)
10.1097/00042560-199801010-00006
Heterosexual HIV-1 transmission and viral load in hemophilic patients.
M. Ragni (1998)
10.1097/00002030-200101260-00011
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults
M. Quigley (2001)
10.1089/088922201750290023
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa.
Fideli US (2001)
10.1016/S0140-6736(99)80008-7
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
L. Guay (1999)
10.1016/S0277-9536(02)00125-9
Dimensions of the emerging orphan crisis in sub-Saharan Africa.
G. Bicego (2003)
10.1097/00002030-199811000-00028
Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
J. Montaner (1998)
10.1001/JAMA.296.7.827
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
S. Hammer (2006)
10.1016/S0140-6736(74)91780-2
Letter: Haemophilia carriers.
Prentice Cr (1974)
10.1097/QAD.0b013e3282ef9fed
Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application
M. Fisher (2007)
10.1164/RCCM.200606-759OC
Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control.
R. Wood (2007)
10.1126/SCIENCE.287.5453.650
A tale of two futures: HIV and antiretroviral therapy in San Francisco.
S. Blower (2000)
10.1097/00002030-200401020-00010
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
T. Porco (2004)
10.1001/JAMA.296.7.855
HIV prevention for a threatened continent: implementing positive prevention in Africa.
R. Bunnell (2006)
10.1086/429411
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
M. Wawer (2005)
Antiretroviral treatment of men infected with human immunodefi ciency virus type 1 reduces the incidence of heterosexual transmission
J Castilla (1994)
10.1097/00002030-200107060-00011
Modelling the effect of combination antiretroviral treatments on HIV incidence
M. Law (2001)
10.1093/INFDIS/145.1.131
Cholera among refugees in Rangsit, Thailand.
J. G. Morris (1982)
Treatment for adult HIV infection.
P. Yeni (2004)
Estimated percentage of people on antiretroviral therapy among those in need , situation as of June 2005
AR Levy
10.1016/S0140-6736(02)11722-3
Time to act: global apathy towards HIV/AIDS is a crime against humanity
R. Hogg (2002)
Infrequent transmission of HIV-1 drug-resistant variants.
S. Yerly (2004)
Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.
D. Pillay (2004)
10.1056/NEJM199201233260404
An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.
C. Daley (1992)
10.1001/JAMA.1985.03350260067028
The incidence rate of acquired immunodeficiency syndrome in selected populations.
A. M. Hardy (1985)
10.1164/RCCM.200303-390OC
Use of isoniazid for latent tuberculosis infection in a public health clinic.
P. Lobue (2003)
10.1056/NEJMOA051871
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
J. Gallant (2006)
10.1097/00002030-200204120-00021
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.
E. Wood (2002)
10.1086/340403
Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1?
M. Hosseinipour (2002)
10.1097/00042560-200203010-00008
Male Viral Load and Heterosexual Transmission of HIV‐1 Subtype E in Northern Thailand
S. Tovanabutra (2002)
10.1097/QAD.0b013e32801424bd
Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding
S. Graham (2007)
10.1056/NEJM199509213331205
Virologic characteristics of subclinical and symptomatic genital herpes infections.
A. Wald (1995)
10.1016/S1473-3099(06)70413-3
The direct costs of HIV/AIDS care.
A. Levy (2006)
10.1128/JCM.26.4.662-667.1988
Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera.
R. Ashley (1988)
10.1001/ARCHINTE.154.17.1971
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission.
M. Musicco (1994)
10.1016/S0140-6736(75)91266-0
HEPANOSTICON IN SCREENING FOR HBsAg
D. Chicot (1975)
10.1001/JAMA.286.20.2560
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
A. Phillips (2001)
10.1016/S0140-6736(04)17053-0
Is “3 by 5” enough? Recalculating the global need for antiretroviral treatment
A. Anema (2004)
10.1016/S0140-6736(06)68337-2
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
The Antiretroviral Therapy in Lower Income Countries Collaboration (2006)
10.1001/jama.1993.03510170086037
Users' guides to the medical literature.
G. Guyatt (1993)
AIDS Res Hum Retroviruses
A. Kamarulzaman (2006)
10.1258/095646206778113032
2006 United Kingdom National Guideline on the Sexual Health of People with HIV: Sexually Transmitted Infections
R. Nandwani (2006)
10.1016/S0140-6736(87)91725-9
RISK FACTORS FOR SEROCONVERSION TO HUMAN IMMUNODEFICIENCY VIRUS AMONG MALE HOMOSEXUALS: Results from the Multicenter AIDS Cohort Study
L. Kingsley (1987)
Why AIDS is exceptional
P. Piot (2005)
10.1016/s0213-005x(05)75040-0
[Prevalence of antiretroviral drug resistance among previously untreated Spanish patients infected with HIV].
A. Guerrero (2005)
10.1097/00002030-200411190-00011
Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal
J. Routy (2004)
10.1097/00002030-199803000-00005
Antiviral effect of double and triple drug combinations amongst HIV‐infected adults: lessons from the implementation of viral load‐driven antiretroviral therapy
R. Hogg (1998)
10.1089/APC.2005.19.760
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda.
M. Bateganya (2005)
10.1016/S0213-005X(05)75040-0
Prevalencia de resistencia a los fármacos antirretrovirales en pacientes españoles infectados por el VIH y sin tratamiento previo
A. Guerrero (2005)
10.1136/bmj.304.6842.1605
Effect of serotesting with counselling on condom use and seroconversion among HIV discordant couples in Africa.
S. Allen (1992)
10.1001/ARCHINTE.1994.00420170123012
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission.
M. Musicco (1994)
10.1056/NEJM200003303421303
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.
T. Quinn (2000)
10.1016/J.AJOG.2007.03.001
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
Halima Dao (2007)
10.1016/S0140-6736(00)04331-2
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda
R. Gray (2001)
10.1097/00042560-199809010-00010
Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.
S. Strathdee (1998)
10.1097/00002030-199710000-00008
Effect of antiviral treatment on the shedding of HIV‐1 in semen
P. Vernazza (1997)
10.1001/JAMA.281.11.1014
Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
C. Nolan (1999)
10.4135/9781412971973.n186
Mexico City : México
J. Cohen (1965)
10.1590/S0042-96862002000700003
Preventing tuberculosis among health workers in Malawi.
A. Harries (2002)
10.1056/NEJM199610103351501
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
S. Hammer (1996)
10.1097/00126334-200203010-00008
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand.
S. Tovanabutra (2002)
10.1089/AID.2005.21.343
Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance.
E. Daar (2005)
10.1093/OXFORDJOURNALS.AJE.A009331
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group.
E. Operskalski (1997)
10.1136/bmj.38665.534595.55
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study
P. Cane (2005)
10.1016/S0140-6736(02)08904-3
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study
M. Badri (2002)
10.1016/S0140-6736(03)13802-0
Decline in the AIDS and death rates in the EuroSIDA study: an observational study
A. Mocroft (2003)
Guidelines for the use of antiretroviral agents in HIV - 1 - infected adults and adolescents . May 4 , 2006
S Cu-Uvin
10.1001/JAMA.279.12.930
A randomized, double-blind trial comparing combinations of Nevirapine, Didanosine, and Zidovudine for HIV-infected patients: the INCAS trial
J. Montaner (1998)
10.1056/NEJMOA012035
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.
H. Côté (2002)
10.1097/01.aids.0000196566.40702.28
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda
R. Bunnell (2006)
10.1016/S0140-6736(89)90589-8
FEMALE TO MALE TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1: RISK FACTORS FOR SEROCONVERSION IN MEN
D. W. Cameron (1989)
10.1128/JVI.71.8.6271-6275.1997
High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors.
P. Gupta (1997)
10.1097/00002030-199905070-00010
Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
G. Davies (1999)
10.1001/JAMA.280.1.78
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
C. Carpenter (1997)
10.1056/AC200609010000001
Adherence to Antiretroviral Therapy: Africa vs. North America
K. Henry (2006)
10.1001/JAMA.274.7.570
Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? The Evidence-Based Medicine Working Group.
R. Hayward (1995)
10.1016/S0140-6736(04)15997-7
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study
F. V. Leth (2004)
10.1016/S0140-6736(06)68337-2
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
P. Braitstein (2006)
10.1016/0140-6736(93)90421-C
HIV-1 and the aetiology of AIDS
M. Schechter (1993)
10.1001/JAMA.296.6.679
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
E. Mills (2006)
10.1016/S1473-3099(02)00346-8
Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?
J. X. Velasco-Hernández (2002)
10.1097/00002030-200001280-00006
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV
P. Vernazza (2000)
10.1126/SCIENCE.6189183
Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).
F. Barré-Sinoussi (1983)
The Search for eff ective HIV vaccines
L Zhang (2005)
10.1126/SCIENCE.1086845
Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS
B. Williams (2003)
10.1073/PNAS.92.26.12100
Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission.
G. Fang (1995)
Mapping the issues
P. Farrell (2002)
10.1097/00002030-200111090-00008
Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil
A. M. de Pinho (2001)
10.1056/NEJM199905273402110
Residual HIV-1 disease in the era of highly active antiretroviral therapy.
R. Pomerantz (1999)
10.1056/NEJM199905273402102
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
M. Furtado (1999)
10.1016/S0140-6736(05)62505-6
Decline in deaths from AIDS due to new antiretrovirals
R. Hogg (1997)
10.1097/01.qai.0000157389.78374.45
Effectiveness of Highly Active Antiretroviral Therapy in Reducing Heterosexual Transmission of HIV
J. Castilla (2005)
10.1001/JAMA.1996.03540020068031
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel
C. C. Carpenter (1996)
10.2105/AJPH.91.7.1060
HIV in the United States at the turn of the century: an epidemic in transition.
J. Karon (2001)
10.1056/NEJM199905273402101
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
L. Zhang (1999)
10.1016/S0140-6736(05)66856-0
Predicting the failure of 3 by 5
A. Harries (2005)
10.1310/4R1B-8F60-B57H-0ECN
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000
A. Fauci (2000)
The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes
D. Barouch (2004)
10.1016/S0140-6736(01)05550-7
Community-based approaches to HIV treatment in resource-poor settings
P. Farmer (2001)
10.1001/JAMA.1995.03530020061033
Risk Factors for Tuberculosis in HIV-lnfected Persons: A Prospective Cohort Study
G. Antonucci (1995)
ciency virus type 1 reduces the incidence of heterosexual transmission
J Castilla (1994)
10.7326/0003-4819-146-8-200704170-00010
Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1
M. Cohen (2007)
Interim policy on collaborative TB / HIV activities.
H. Getahun (2004)
Why AIDS is exceptional . Speech given at the London School of Economics , London , Feb 8 , 2005 . 2 UNAIDS . 2006 Report on the global AIDS epidemic . Annex 2 : HIV / AIDS estimates and data , 2005
P Piot
Comparison of fi rst - line antiretroviral therapy with regimens including nevirapine , efavirenz , or both drugs , plus stavudine and lamivudine : a randomised open - label trial , the 2 NN Study
JE Gallant (2004)
10.1001/JAMA.276.2.146
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
C. Carpenter (1996)
10.1056/NEJM199912163412501
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
S. Staszewski (1999)
10.1097/00002030-200003100-00015
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA
S. Cu-Uvin (2000)
10.1001/JAMA.1983.03330370053031
If nothing goes wrong, is everything all right? Interpreting zero numerators.
J. Hanley (1983)
10.1056/NEJMP058146
The search for effective HIV vaccines.
H. Markel (2005)
10.1086/422601
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan.
C. Fang (2004)
10.1016/S0140-6736(06)69573-1
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
N. Gandhi (2006)
10.1186/1742-6405-3-2
Expanding access to HIV prevention
H. Gayle (2006)
10.1097/00002030-199312000-00005
The mortality and pathology of HIV infection in a West African city
S. Lucas (1993)
Why AIDS is exceptional . Speech given at the London School of Economics , London , Feb 8 , 2005 . 2 UNAIDS . 2006 Report on the global AIDS epidemic . Annex 2 : HIV / AIDS estimates and data , 2005
JM Karon
Financing the expanded response to AIDS : HIV vaccine and microbicide research and development , 2005
T Kerr
Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa.
J. Day (2006)
VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
Aria (2000)
10.1001/JAMA.279.6.450
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
R. Hogg (1998)
Grupo de Estudio de las Resistencias Primarias del VIH en Espana. Prevalence of antiretroviral drug resistance among previously untreated Spanish patients infected with HIV
A Guerrero (2005)
10.1038/NM1103-1343B
World Bank meeting concludes drug resistance should not prevent distribution of antiretroviral therapy to poor countries
D. Kuritzkes (2003)
10.1001/JAMA.283.9.1175
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice.
K. D. De Cock (2000)
10.1016/S0140-6736(06)68392-X
WHO's new Stop TB Strategy
M. Raviglione (2006)



This paper is referenced by
En quoi les pratiques de RdRD peuvent-elles s'intégrer dans les stratégies de prévention et de soin et les améliorer, dans tous les secteurs des addictions ? Quelle place des usagers dans ces modalités d'action ?
J. Delile (2017)
10.1136/sti.2010.044560
Increased HIV testing and reduced undiagnosed infection among gay men in Scotland, 2005–8: support for the opt-out testing policy?
L. McDaid (2011)
10.1128/AAC.01490-15
HIV Drug Resistance Testing by High-Multiplex “Wide” Sequencing on the MiSeq Instrument
H. Lapointe (2015)
10.1097/QAI.0b013e31827e4992
Global Policy Review of Antiretroviral Therapy Eligibility Criteria for Treatment and Prevention of HIV and Tuberculosis in Adults, Pregnant Women, and Serodiscordant Couples
S. Gupta (2013)
10.1016/J.JRI.2007.02.002
The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission.
R. Kaul (2008)
10.1371/journal.pcbi.1002015
Autonomous Targeting of Infectious Superspreaders Using Engineered Transmissible Therapies
Vincent T. Metzger (2011)
10.1371/journal.pmed.1002534
HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries
Olga Tymejczyk (2018)
10.1371/journal.pone.0002212
Understanding the Impact of Male Circumcision Interventions on the Spread of HIV in Southern Africa
T. Hallett (2008)
10.2174/157016211798038533
Modelling the Impact of Antiretroviral Therapy on the Epidemic of HIV
B. Williams (2011)
10.1097/QAD.0b013e3282fbd1ed
A review of barriers and facilitators of HIV treatment among injection drug users
E. Wood (2008)
Can we rely on the antiretroviral treatment as the only means for human immunodeficiency virus prevention? A Public Health perspective
Antons Mozalevskis (2019)
10.2139/SSRN.2794757
Modeling the Global Public Health Determinants of HIV/AIDS-Related Deaths
Jandryle U. Trondillo (2016)
10.1101/2019.12.30.890822
An instrument to assess HIV-related knowledge and adjustment to HIV+ status, and their association with anti-retroviral adherence
M. B. Laws (2019)
10.3934/mbe.2013.10.1673
Increasing survival time decreases the cost-effectiveness of using "test & treat'' to eliminate HIV epidemics.
B. Wagner (2013)
10.1097/QAD.0b013e32834b4ced
Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world
K. Venkatesh (2011)
10.1016/J.APM.2012.09.065
A novel time delayed HIV/AIDS model with vaccination & antiretroviral therapy and its stability analysis
Defang Liu (2013)
10.7326/0003-4819-146-8-200704170-00013
Hungering for HAART
J. Montaner (2007)
10.17269/CJPH.107.5318
Prevalence of HIV infection and acceptability of point-of-care testing in a Canadian inner-city emergency department
R. Stenstrom (2016)
Modelling the Relationship between Antiretroviral Treatment and HIV Prevention : The Limits of Spectrum ’ s AIDS Impact Model in a Changing Policy Environment
(2007)
10.12988/imf.2016.6797
Mathematical model on the effect of hospital admission for HIV infected individuals on the rate of transmission and mortality
Okaka C. Akinyi (2016)
10.1300/J187v06n01_02
HIV Treatment Adherence Research and Intervention
M. Stirratt (2007)
Test and treat in HIV : success could depend on rapid detection
N. Padian (2011)
10.1016/j.cmi.2017.08.012
Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men.
J. Coll (2018)
10.1155/2015/381870
Gaps in the hepatitis C continuum of care among sex workers in Vancouver, British Columbia: Implications for voluntary hepatitis C virus testing, treatment and care.
M. Socías (2015)
10.1097/QAI.0b013e3182a8efc3
Trends in Plasma HIV-RNA Suppression and Antiretroviral Resistance in British Columbia, 1997–2010
A. Cescon (2014)
10.1007/s00038-009-8078-5
Conceptualizing the integration of HIV treatment and prevention: findings from a process evaluation of a community-based, national capacity-building intervention
E. Mykhalovskiy (2009)
10.2217/FVL.10.38
How HIV treatment could result in effective prevention.
K. Venkatesh (2010)
10.1111/J.1467-8268.2009.00205.X
HIV/AIDS Knowledge and behaviour: Have information campaigns reduced HIV infection? The case of Kenya
M. Frölich (2009)
10.1097/QAD.0b013e32835ca2dd
The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis
Í. Cremin (2013)
10.1097/COH.0b013e32832c06c3
Early treatment of HIV: implications for resource-limited settings
C. V. Hobbs (2009)
10.1093/infdis/jis029
Tuberculosis and HIV control in sub-Saharan African prisons: "thinking outside the prison cell".
S. Reid (2012)
From AZT to treatment as prevention. The evolution of antiretroviral therapy for HIV/AIDS
C. Duarte (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar